Table 3.
Sclerostin Versus Clinical Risk Factors (ALSPAC/LURIC)
| LURIC (N = 2054) | ALSPAC (N = 3015) | |||||
|---|---|---|---|---|---|---|
| Exposure | Outcome | Model | β (95% CI) | p | β (95% CI) | p |
| Sclerostin | eGFR | 1 | −0.36 (−0.40, –0.31) | <0.001 | −0.17 (−0.21, –0.14) | <0.001 |
| Sclerostin | eGFR | 2 | −0.29 (−0.33, –0.25) | <0.001 | −0.11 (−0.15, –0.08) | <0.001 |
| OR (95% CI) | p | OR (95% CI) | p | |||
|---|---|---|---|---|---|---|
| Sclerostin | Diabetes | 1 | 1.39 (1.24, 1.55) | <0.001 | 1.31 (1.03, 1.68) | 0.030 |
| Sclerostin | Diabetes | 2 | 1.23 (1.10, 1.36) | <0.001 | 1.37 (1.06, 1.78) | 0.018 |
| Sclerostin | High glucose | 1 | 1.20 (1.08, 1.33) | <0.001 | 1.14 (0.90, 1.44) | 0.272 |
| Sclerostin | High glucose | 2 | 1.15 (1.04, 1.27) | 0.009 | 1.14 (0.89, 1.46) | 0.286 |
| Sclerostin | Hypertension | 1 | 1.23 (1.09, 1.40) | 0.001 | 1.24 (1.07, 1.43) | 0.005 |
| Sclerostin | Hypertension | 2 | 1.04 (0.93, 1.17) | 0.459 | 1.19 (1.02, 1.39) | 0.030 |
LURIC = Ludwigshafen Risk and Cardiovascular Health; ALSPAC = Avon Longitudinal Study of Parents and Children; CI = confidence interval; eGFR = estimated glomerular filtration rate; OR = odds ratio.
Table shows results of linear/logistic regression analysis. Results are SD change in outcome/odds of outcome per SD increase in sclerostin, 95% CI, and p value. High glucose based on fasting plasma glucose concentration ≥7.0 mmol/L (whole blood ≥6.1 mmol/L). Model 1: unadjusted; model 2: adjusted for age and ethnic group (ALSPAC) and sex (LURIC), body mass index, smoking, and social deprivation.